EI

259.5

-0.42%↓

MRK1

110

-0.23%↓

SHL.DE

47.08

-0.32%↓

ARGX

647.8

+0.09%↑

FRE

47.13

+0.23%↑

EI

259.5

-0.42%↓

MRK1

110

-0.23%↓

SHL.DE

47.08

-0.32%↓

ARGX

647.8

+0.09%↑

FRE

47.13

+0.23%↑

EI

259.5

-0.42%↓

MRK1

110

-0.23%↓

SHL.DE

47.08

-0.32%↓

ARGX

647.8

+0.09%↑

FRE

47.13

+0.23%↑

EI

259.5

-0.42%↓

MRK1

110

-0.23%↓

SHL.DE

47.08

-0.32%↓

ARGX

647.8

+0.09%↑

FRE

47.13

+0.23%↑

EI

259.5

-0.42%↓

MRK1

110

-0.23%↓

SHL.DE

47.08

-0.32%↓

ARGX

647.8

+0.09%↑

FRE

47.13

+0.23%↑

Search

Sanofi SA

Abierto

SectorSanidad

80.39 2

Resumen

Variación precio

24h

Actual

Mínimo

78.88

Máximo

81.05

Métricas clave

By Trading Economics

Ingresos

1.1B

2.9B

Ventas

129M

11B

P/B

Media del Sector

16.445

35.733

BPA

1.59

Rentabilidad por dividendo

4.64

Margen de beneficios

27.303

Empleados

82,878

EBITDA

-881M

1.9B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+35.85% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

4.64%

3.13%

Próximas Ganancias

24 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

239M

104B

Apertura anterior

78.39

Cierre anterior

80.39

Noticias sobre sentimiento de mercado

By Acuity

42%

58%

157 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Sanofi SA Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 sept 2025, 08:58 UTC

Principales Movimientos del Mercado

Sanofi Shares Sink as Experimental Drug Results Disappoint

4 ago 2025, 10:06 UTC

Principales Movimientos del Mercado

U.K. Bank Shares Rise After Car-Loan Ruling Softens Industry Blow -- Update

31 jul 2025, 06:00 UTC

Ganancias

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

30 jul 2025, 10:20 UTC

Ganancias

Santander Reports Higher Profit, but Regional Picture is Mixed -- Update

5 sept 2025, 08:24 UTC

Charlas de Mercado

Sanofi's Eczema Drug Candidate Could Still Become a Blockbuster -- Market Talk

5 sept 2025, 06:55 UTC

Charlas de Mercado

Sanofi Share Fall After Eczema Trial Results Looks Overdone -- Market Talk

28 ago 2025, 09:00 UTC

Charlas de Mercado

Santander Could Deliver Even Higher Returns -- Market Talk

6 ago 2025, 05:02 UTC

Adquisiciones, fusiones, absorciones

Sanofi Completes the Acquisition of Vigil Neuroscience

6 ago 2025, 05:00 UTC

Adquisiciones, fusiones, absorciones

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1 ago 2025, 13:16 UTC

Ganancias

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 ago 2025, 12:40 UTC

Ganancias

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31 jul 2025, 08:15 UTC

Charlas de Mercado
Ganancias

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31 jul 2025, 05:56 UTC

Charlas de Mercado
Ganancias

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31 jul 2025, 05:30 UTC

Ganancias

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31 jul 2025, 05:30 UTC

Ganancias

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31 jul 2025, 05:30 UTC

Ganancias

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

31 jul 2025, 05:30 UTC

Ganancias

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

31 jul 2025, 05:30 UTC

Ganancias

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

31 jul 2025, 05:30 UTC

Ganancias

Sanofi 2Q Business Operating Profit EUR2.46B

31 jul 2025, 05:30 UTC

Ganancias

Sanofi 2Q Adj EPS EUR1.59

31 jul 2025, 05:30 UTC

Ganancias

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

31 jul 2025, 05:30 UTC

Ganancias

Analysts Saw Sanofi 2Q Net Sales at EUR9.77B

31 jul 2025, 05:30 UTC

Ganancias

Sanofi 2Q Net Pft EUR3.94B

31 jul 2025, 05:30 UTC

Ganancias

Analysts Saw Sanofi 2Q Business EPS at EUR1.64

31 jul 2025, 05:30 UTC

Ganancias

Sanofi Now Expects 2025 Sales Growth at Constant Currency at High Single-Digit Percentage

31 jul 2025, 05:30 UTC

Ganancias

Sanofi Had Seen 2025 Sales Growth at Constant Currency at Mid-To-High Single-digit

31 jul 2025, 05:30 UTC

Ganancias

Sanofi 2Q Sales EUR9.99B

31 jul 2025, 05:30 UTC

Ganancias

Sanofi Backs 2025 EPS Adj View

31 jul 2025, 05:30 UTC

Ganancias

Sanofi Narrows 2025 Sales View

31 jul 2025, 05:30 UTC

Ganancias

Sanofi Confirms Expectations of Business EPS Rebound in 2025 Before Buybacks

Comparación entre iguales

Cambio de precio

Sanofi SA previsión

Precio Objetivo

By TipRanks

35.85% repunte

Estimación a 12 Meses

Media 107.997 EUR  35.85%

Máximo 120 EUR

Mínimo 94 EUR

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

11

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

91.3 / 96.1Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

157 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat